Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly - Updated Oct 20, 2017 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On another record day for the major benchmarks, shares of Skechers skyrocketed on earnings and Celgene tumbled after discontinuing a drug trial.

Stocks rose strongly on Friday to close the market's sixth straight week of gains. The Dow Jones Industrial Average (^DJI 1.05%) and the S&P 500 (^GSPC 1.05%) both added more than half a percent to post record highs.

Today's stock market

Index Percentage Change Point Change
Dow 0.71% 165.59
S&P 500 0.51% 13.11

Data source: Yahoo! Finance.

Financials led the way today, and the Financial Select Sector SPDR ETF (XLF 1.37%) ended with a 1.2% gain. Industrials also rose; the Industrial Select SPDR ETF (XLI 0.87%) closed up 1.1%.

As for individual stocks, shares of Skechers U.S.A. (SKX -0.81%) soared after the company reported higher-than-expected profits in its latest quarter, and Celgene (CELG) tumbled after announcing it was discontinuing some drug trials for one of its most promising drug candidates.

Rising stock price graph and stock prices.

Image source: Getty Images.

Skechers sprints ahead on a strong quarter

Shares of footwear seller Skechers took a huge leap today, gaining 41.5% after the company announced Q3 results that beat expectations for sales and blew away the company's projections for profit. Revenue increased 16.2% to $1.095 billion compared with earlier guidance of $1.05 billion to $1.075 billion, and earnings per share were up 40% to $0.59 after the company had told analysts to expect $0.42 to $0.47. 

Sales growth was largely powered by the company's international business; the international wholesale channel grew sales a whopping 25.7%, and total international sales comprised 53% of revenye, up from 48% in the first half of the year. The company-owned retail business also boomed, up 18.6%, with comparable-store sales growing 3.1% in the U.S. and 4.4% overall. Domestic wholesale revenue rose 1.4%.

"Three consecutive record quarters in 2017 and continued growth across our three distribution channels, including double-digit gains in international and an additional ten stores opened in the fourth quarter to date, are a testament to the strength of our brand," said COO and CFO David Weinberg in the press release.

The profit numbers had tailwinds of a lower tax rate and stronger currencies overseas, but even without those, Skechers has been mounting a sales growth comeback from a disappointing 2016. Last quarter's results were disappointing from a profit point of view, but this quarter put all the pieces together.

Celgene plummets after discontinuing a drug trials

Celgene saw its shares crater 10.8% today after the biotech giant announced it was discontinuing trials of drug candidate mongersen as a treatment for Crohn's disease. The company decided to stop two trials and not start a planned third one due to a risk/benefit analysis of interim results that apparently concluded the drug was not effective enough. 

"Crohn's disease is a debilitating condition with few effective long-term treatment options," said President and COO Scott Smith in the press release. "While we are disappointed with the results of REVOLVE, we remain committed to advancing our portfolio of novel medicines for patients suffering from this disease and other inflammatory bowel disorders."

Industry analysis service EvaluatePharma estimated in May that the net present value of mongersen sales is $3.3 billion, so this is certainly a blow to Celgene, with revenue currently running at about $12 billion a year and expected to grow to $21 billion by 2020. But the impact may be not be as severe as it appears. Mongersen may not be a total loss, as it is in phase 2 trials for ulcerative colitis. Celgene is also testing another pipeline drug for Crohn's, ozanimod, and if that drug is successful, it may nab some of the market that mongersen would have. 

Today's news disappointed investors, but long-term fans of the stock have plenty of reasons to continue to be optimistic about the many opportunities remaining in the company's extensive pipeline. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
Skechers U.S.A., Inc. Stock Quote
Skechers U.S.A., Inc.
SKX
$35.29 (-0.81%) $0.29
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$31,097.26 (1.05%) $321.83
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,825.33 (1.05%) $39.95
The Select Sector SPDR Trust - The Financial Select Sector SPDR Fund Stock Quote
The Select Sector SPDR Trust - The Financial Select Sector SPDR Fund
XLF
$31.88 (1.37%) $0.43
The Select Sector SPDR Trust - The Industrial Select Sector SPDR Fund Stock Quote
The Select Sector SPDR Trust - The Industrial Select Sector SPDR Fund
XLI
$88.10 (0.87%) $0.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.